Target Price | SEK354.45 |
Price | SEK269.00 |
Potential |
31.77%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target Swedish Orphan Biovitrum 2026 .
The average Swedish Orphan Biovitrum target price is SEK354.45.
This is
31.77%
register free of charge
SEK402.15
49.50%
register free of charge
SEK287.85
7.01%
register free of charge
|
|
A rating was issued by 19 analysts: 15 Analysts recommend Swedish Orphan Biovitrum to buy, 3 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Swedish Orphan Biovitrum stock has an average upside potential 2026 of
31.77%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion SEK | 26.03 | 28.75 |
17.65% | 10.44% | |
EBITDA Margin | 36.55% | 37.18% |
3.75% | 1.72% | |
Net Margin | 14.93% | 17.90% |
37.08% | 19.92% |
16 Analysts have issued a sales forecast Swedish Orphan Biovitrum 2025 . The average Swedish Orphan Biovitrum sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Swedish Orphan Biovitrum EBITDA forecast 2025. The average Swedish Orphan Biovitrum EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Swedish Orphan Biovitrum Analysts have issued a net profit forecast 2025. The average Swedish Orphan Biovitrum net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share SEK | 11.24 | 14.93 |
52.10% | 32.83% | |
P/E | 18.19 | |
EV/Sales | 3.74 |
16 Analysts have issued a Swedish Orphan Biovitrum forecast for earnings per share. The average Swedish Orphan Biovitrum EPS is
This results in the following potential growth metrics and future valuations:
Swedish Orphan Biovitrum...
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Locked
➜
Locked
|
Locked | Jul 17 2025 |
HANDELSBANKEN CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | Jul 16 2025 |
PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Jul 16 2025 |
HSBC |
Locked
➜
Locked
|
Locked | May 25 2025 |
DNB CARNEGIE |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
DNB MARKETS |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
BERENBERG |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
Analyst Rating | Date |
---|---|
Locked
BERENBERG:
Locked
➜
Locked
|
Jul 17 2025 |
Locked
HANDELSBANKEN CAPITAL MARKETS:
Locked
➜
Locked
|
Jul 16 2025 |
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Jul 16 2025 |
Locked
HSBC:
Locked
➜
Locked
|
May 25 2025 |
Locked
DNB CARNEGIE:
Locked
➜
Locked
|
Apr 02 2025 |
Locked
DNB MARKETS:
Locked
➜
Locked
|
Apr 02 2025 |
Locked
BERENBERG:
Locked
➜
Locked
|
Mar 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.